NURSING PHARMACOLOGY EXAM
MASTER BANK HIGH-YIELD LEHNE'S
QUESTIONS WITH EXPLANATIONS
Ace your nursing pharmacology exams with this comprehensive
premium test bank meticulously aligned with the latest edition of
Lehne’s flagship textbook. Every single NCLEX-style multiple-
choice question features highlighted correct answers and highly
detailed, evidence-based rationales designed to master complex
drug classes. It is the ultimate high-yield study tool for students
aiming to maximize their clinical judgment skills and guarantee a
passing score.
Chapter 1–4: Introduction to Pharmacology &
Pharmacokinetics
Question 1
A nurse is preparing to administer an intravenous
medication that is highly water-soluble. Which
pharmacokinetic property should the nurse consider
regarding this drug?
A. It will easily cross the blood-brain barrier.
B. It requires active transport to enter most cells.
C. It will have a very large volume of distribution.
D. It will pass rapidly through the capillary
fenestrations of standard tissues.
Rationale: Highly water-soluble drugs cannot
easily pass through lipid membranes like the
blood-brain barrier, but they freely pass through
,the large gaps (fenestrations) in standard
capillary beds. They tend to stay within the
vascular space, leading to a smaller volume of
distribution.
Question 2
The nurse administers an oral medication that
undergoes significant first-pass metabolism. What is
the clinical implication of this phenomenon?
A. The drug will have increased bioavailability when
taken with food.
B. A fraction of the active drug is inactivated by the
liver before reaching systemic circulation.
C. The drug must be administered with an antacid to
prevent stomach degradation.
D. The renal clearance rate of the drug will be
dramatically increased.
Rationale: First-pass metabolism occurs when
an oral drug is absorbed from the GI tract into
the portal circulation and metabolized by the
liver before it ever reaches the systemic
bloodstream, significantly reducing its active
bioavailability.
Question 3
A patient is receiving a drug that is a known hepatic
enzyme inducer. The nurse should monitor for which
,effect if the patient is taking other medications
metabolized by the same pathway?
A. Decreased therapeutic effects of the co-
administered medications.
B. Prolonged half-life of the co-administered
medications.
C. Increased risk of toxicities from the companion
drugs.
D. Increased plasma drug levels of the companion
drugs.
Rationale: Hepatic enzyme inducers stimulate
the synthesis of cytochrome P450 enzymes. This
accelerates the metabolism of companion drugs,
lowering their blood levels and reducing their
therapeutic effectiveness.
Question 4
When evaluating a new medication, the nurse notes
that it has a very narrow therapeutic index. What
does this property indicate to the healthcare team?
A. The drug is highly potent and requires a very
small dose.
B. The drug safe-dosage range is wide and does not
require serum monitoring.
C. The difference between a safe therapeutic dose
and a toxic dose is very small.
, D. The medication is only effective against a specific
subset of receptor sites.
Rationale: A narrow therapeutic index means
that the margin of safety between the minimum
effective concentration and the minimum toxic
concentration is small, requiring close
monitoring of serum drug levels.
Question 5
An older adult patient with a low serum albumin level
is prescribed a highly protein-bound medication. The
nurse should assess the patient for which primary
risk?
A. Reduced drug distribution to target organs.
B. Rapid renal excretion of the bound drug fraction.
C. Increased risk of drug toxicity due to higher free
drug levels.
D. Failure of the drug to bind to peripheral cell
receptors.
Rationale: When albumin is low, there are fewer
binding sites available. This leaves a higher
concentration of free, active drug in the plasma,
which increases the intensity of the drug's effect
and raises the risk of toxicity.
MASTER BANK HIGH-YIELD LEHNE'S
QUESTIONS WITH EXPLANATIONS
Ace your nursing pharmacology exams with this comprehensive
premium test bank meticulously aligned with the latest edition of
Lehne’s flagship textbook. Every single NCLEX-style multiple-
choice question features highlighted correct answers and highly
detailed, evidence-based rationales designed to master complex
drug classes. It is the ultimate high-yield study tool for students
aiming to maximize their clinical judgment skills and guarantee a
passing score.
Chapter 1–4: Introduction to Pharmacology &
Pharmacokinetics
Question 1
A nurse is preparing to administer an intravenous
medication that is highly water-soluble. Which
pharmacokinetic property should the nurse consider
regarding this drug?
A. It will easily cross the blood-brain barrier.
B. It requires active transport to enter most cells.
C. It will have a very large volume of distribution.
D. It will pass rapidly through the capillary
fenestrations of standard tissues.
Rationale: Highly water-soluble drugs cannot
easily pass through lipid membranes like the
blood-brain barrier, but they freely pass through
,the large gaps (fenestrations) in standard
capillary beds. They tend to stay within the
vascular space, leading to a smaller volume of
distribution.
Question 2
The nurse administers an oral medication that
undergoes significant first-pass metabolism. What is
the clinical implication of this phenomenon?
A. The drug will have increased bioavailability when
taken with food.
B. A fraction of the active drug is inactivated by the
liver before reaching systemic circulation.
C. The drug must be administered with an antacid to
prevent stomach degradation.
D. The renal clearance rate of the drug will be
dramatically increased.
Rationale: First-pass metabolism occurs when
an oral drug is absorbed from the GI tract into
the portal circulation and metabolized by the
liver before it ever reaches the systemic
bloodstream, significantly reducing its active
bioavailability.
Question 3
A patient is receiving a drug that is a known hepatic
enzyme inducer. The nurse should monitor for which
,effect if the patient is taking other medications
metabolized by the same pathway?
A. Decreased therapeutic effects of the co-
administered medications.
B. Prolonged half-life of the co-administered
medications.
C. Increased risk of toxicities from the companion
drugs.
D. Increased plasma drug levels of the companion
drugs.
Rationale: Hepatic enzyme inducers stimulate
the synthesis of cytochrome P450 enzymes. This
accelerates the metabolism of companion drugs,
lowering their blood levels and reducing their
therapeutic effectiveness.
Question 4
When evaluating a new medication, the nurse notes
that it has a very narrow therapeutic index. What
does this property indicate to the healthcare team?
A. The drug is highly potent and requires a very
small dose.
B. The drug safe-dosage range is wide and does not
require serum monitoring.
C. The difference between a safe therapeutic dose
and a toxic dose is very small.
, D. The medication is only effective against a specific
subset of receptor sites.
Rationale: A narrow therapeutic index means
that the margin of safety between the minimum
effective concentration and the minimum toxic
concentration is small, requiring close
monitoring of serum drug levels.
Question 5
An older adult patient with a low serum albumin level
is prescribed a highly protein-bound medication. The
nurse should assess the patient for which primary
risk?
A. Reduced drug distribution to target organs.
B. Rapid renal excretion of the bound drug fraction.
C. Increased risk of drug toxicity due to higher free
drug levels.
D. Failure of the drug to bind to peripheral cell
receptors.
Rationale: When albumin is low, there are fewer
binding sites available. This leaves a higher
concentration of free, active drug in the plasma,
which increases the intensity of the drug's effect
and raises the risk of toxicity.
